Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Autor: Dummer, Reinhard, Ascierto, Paolo A, Gogas, Helen J, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion Sileni, Vanna, Dutriaux, Caroline, de Groot, Jan Willem B, Yamazaki, Naoya, Loquai, Carmen, Moutouh-de Parseval, Laure A, Pickard, Michael D, Sandor, Victor, Robert, Caroline, Flaherty, Keith T

Publikováno v: In The Lancet Oncology October 2018 19(10):1315-1327

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer : safety lead-in results from the phase III BEACON colorectal cancer study

Autor: Van Cutsem, Eric, Huijberts, Sanne, Grothey, Axel, Yaeger, Rona, Cuyle, Pieter-Jan, Elez, Elena, Fakih, Marwan, Montagut, Clara, Peeters, Marc, Yoshino, Takayuki, Wasan, Harpreet, Desai, Jayesh, Ciardiello, Fortunato, Gollerkeri, Ashwin, Christy-Bittel, Janna, Maharry, Kati, Sandor, Victor, Schellens, Jan H.M., Kopetz, Scott, Tabernero, Josep, VHIR Vall d'Hebron Institut de Recerca

Publikováno v: Journal of clinical oncology
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Journal of clinical oncology : official journal of the American Society of Clinical Oncology

PURPOSE To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E–mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88557e46de023883c25af21fce87c596
https://hdl.handle.net/10067/1613370151162165141

Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma

Autor: Dummer, Reinhard Ascierto, Paolo Antonio Gogas, Helen and Arance, Ana M. Mandala, Mario Liszkay, Gabriella Garbe, Claus Schadendorf, Dirk Krajsova, Ivana Gutzmer, Ralf and Chiarion-Sileni, Vanna Dutriaux, Caroline de Groot, Jan Willem and Yamazaki, Naoya Loquai, Carmen De Parseval, Laure A. and Pickard, Michael D. Sandor, Victor Robert, Caroline and Flaherty, Keith

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::159313201c66be6cae7f62064285dece
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3179870

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Autor: Vannucchi, Alessandro M, Kantarjian, Hagop M., Kiladjian, Jean Jacques, Gotlib, Jason, Cervantes, Francisco, Mesa, Ruben A., Sarlis, Nicholas J., Peng, Wei, Sandor, Victor, Gopalakrishna, Prashanth, Hmissi, Abdel, Stalbovskaya, Viktoriya, Gupta, Vikas, Harrison, Claire, Verstovsek, Srdan, Passamonti, Francesco

Publikováno v: Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona

Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies. In addition, ruxolitinib was associated with prolonged survival compared wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50f3be309354449973737a38439e0655
http://hdl.handle.net/11383/2062567